126 related articles for article (PubMed ID: 17312272)
1. Impaired peroxisome proliferator-activated receptor gamma function through mutation of a conserved salt bridge (R425C) in familial partial lipodystrophy.
Jeninga EH; van Beekum O; van Dijk AD; Hamers N; Hendriks-Stegeman BI; Bonvin AM; Berger R; Kalkhoven E
Mol Endocrinol; 2007 May; 21(5):1049-65. PubMed ID: 17312272
[TBL] [Abstract][Full Text] [Related]
2. New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.
Lüdtke A; Buettner J; Schmidt HH; Worman HJ
J Med Genet; 2007 Sep; 44(9):e88. PubMed ID: 17766367
[TBL] [Abstract][Full Text] [Related]
3. Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma.
Monajemi H; Zhang L; Li G; Jeninga EH; Cao H; Maas M; Brouwer CB; Kalkhoven E; Stroes E; Hegele RA; Leff T
J Clin Endocrinol Metab; 2007 May; 92(5):1606-12. PubMed ID: 17299075
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy.
Lüdtke A; Buettner J; Wu W; Muchir A; Schroeter A; Zinn-Justin S; Spuler S; Schmidt HH; Worman HJ
J Clin Endocrinol Metab; 2007 Jun; 92(6):2248-55. PubMed ID: 17356052
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system.
Auclair M; Vigouroux C; Boccara F; Capel E; Vigeral C; Guerci B; Lascols O; Capeau J; Caron-Debarle M
Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):829-38. PubMed ID: 23393388
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of the transactivation deficiency of the human PPARγ F360L mutant associated with familial partial lipodystrophy.
Lori C; Pasquo A; Montanari R; Capelli D; Consalvi V; Chiaraluce R; Cervoni L; Loiodice F; Laghezza A; Aschi M; Giorgi A; Pochetti G
Acta Crystallogr D Biol Crystallogr; 2014 Jul; 70(Pt 7):1965-76. PubMed ID: 25004973
[TBL] [Abstract][Full Text] [Related]
7. Novel peroxisome proliferator-activated receptor gamma mutation in a family with familial partial lipodystrophy type 3.
Miehle K; Porrmann J; Mitter D; Stumvoll M; Glaser C; Fasshauer M; Hoffmann K
Clin Endocrinol (Oxf); 2016 Jan; 84(1):141-8. PubMed ID: 26119484
[TBL] [Abstract][Full Text] [Related]
8. Lessons from human mutations in PPARgamma.
Hegele RA
Int J Obes (Lond); 2005 Mar; 29 Suppl 1():S31-5. PubMed ID: 15711581
[TBL] [Abstract][Full Text] [Related]
9. Natural helix 9 mutants of PPARγ differently affect its transcriptional activity.
Broekema MF; Massink MPG; Donato C; de Ligt J; Schaarschmidt J; Borgman A; Schooneman MG; Melchers D; Gerding MN; Houtman R; Bonvin AMJJ; Majithia AR; Monajemi H; van Haaften GW; Soeters MR; Kalkhoven E
Mol Metab; 2019 Feb; 20():115-127. PubMed ID: 30595551
[TBL] [Abstract][Full Text] [Related]
10. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy.
Agarwal AK; Garg A
J Clin Endocrinol Metab; 2002 Jan; 87(1):408-11. PubMed ID: 11788685
[TBL] [Abstract][Full Text] [Related]
11. A frameshift mutation in peroxisome-proliferator-activated receptor-gamma in familial partial lipodystrophy subtype 3 (FPLD3; MIM 604367).
Hegele RA; Ur E; Ransom TP; Cao H
Clin Genet; 2006 Oct; 70(4):360-2. PubMed ID: 16965332
[No Abstract] [Full Text] [Related]
12. Vascular placental abnormalities and newborn death in a pregnant diabetic woman with familial partial lipodystrophy type 3: a possible role for peroxisome proliferator-activated receptor γ.
Castell AL; Hiéronimus S; Lascols O; Fournier T; Fénichel P
Diabetes Metab; 2012 Oct; 38(4):367-9. PubMed ID: 22559930
[TBL] [Abstract][Full Text] [Related]
13. A Pharmacogenetic Approach to the Treatment of Patients With
Agostini M; Schoenmakers E; Beig J; Fairall L; Szatmari I; Rajanayagam O; Muskett FW; Adams C; Marais AD; O'Rahilly S; Semple RK; Nagy L; Majithia AR; Schwabe JWR; Blom DJ; Murphy R; Chatterjee K; Savage DB
Diabetes; 2018 Jun; 67(6):1086-1092. PubMed ID: 29622583
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor gamma-ligand-binding domain mutations associated with familial partial lipodystrophy type 3 disrupt human trophoblast fusion and fibroblast migration.
Shoaito H; Chauveau S; Gosseaume C; Bourguet W; Vigouroux C; Vatier C; Pienkowski C; Fournier T; Degrelle SA
J Cell Mol Med; 2020 Jul; 24(13):7660-7669. PubMed ID: 32519441
[TBL] [Abstract][Full Text] [Related]
15. Altered promoter recycling rates contribute to dominant-negative activity of human peroxisome proliferator-activated receptor-gamma mutations associated with diabetes.
Li G; Leff T
Mol Endocrinol; 2007 Apr; 21(4):857-64. PubMed ID: 17227883
[TBL] [Abstract][Full Text] [Related]
16. 3-phosphoinositide-dependent protein kinase-1 activates the peroxisome proliferator-activated receptor-gamma and promotes adipocyte differentiation.
Yin Y; Yuan H; Wang C; Pattabiraman N; Rao M; Pestell RG; Glazer RI
Mol Endocrinol; 2006 Feb; 20(2):268-78. PubMed ID: 16150867
[TBL] [Abstract][Full Text] [Related]
17. Rational discovery of a novel interface for a coactivator in the peroxisome proliferator-activated receptor gamma: theoretical implications of impairment in type 2 diabetes mellitus.
Shiraki T; Kodama TS; Jingami H; Kamiya N
Proteins; 2005 Feb; 58(2):418-25. PubMed ID: 15558556
[TBL] [Abstract][Full Text] [Related]
18. The novel loss of function Ile354Val mutation in PPARG causes familial partial lipodystrophy.
Padova G; Prudente S; Vinciguerra F; Sudano D; Baratta R; Bellacchio E; Trischitta V; Vallone A; Sciacca L; Frittitta L
Acta Diabetol; 2020 May; 57(5):589-596. PubMed ID: 31863320
[TBL] [Abstract][Full Text] [Related]
19. Case Report: A New Peroxisome Proliferator-Activated Receptor Gamma Mutation Causes Familial Partial Lipodystrophy Type 3 in a Chinese Patient.
Chen X; Ma Z; Chen P; Song X; Li W; Yu X; Xie J
Front Endocrinol (Lausanne); 2022; 13():830708. PubMed ID: 35422762
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma.
Agostini M; Gurnell M; Savage DB; Wood EM; Smith AG; Rajanayagam O; Garnes KT; Levinson SH; Xu HE; Schwabe JW; Willson TM; O'Rahilly S; Chatterjee VK
Endocrinology; 2004 Apr; 145(4):1527-38. PubMed ID: 14657011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
